Glenmark Pharmaceuticals Limited — Q2 FY26
Glenmark's Q2 FY26 consolidated revenue surged 76% YoY to ₹6,047 crore, driven by the ISB 2001 out-licensing deal which contributed ₹4,466 crore in North America.
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q1 FY26
Europe and emerging markets to return to double-digit growth in FY26
Europe region expected to return to double-digit growth from Q2 onwards, and emerging markets anticipated to grow double-digit on constant currency basis in FY26.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1